These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 19836385)

  • 1. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.
    Holoch PA; Griffith TS
    Eur J Pharmacol; 2009 Dec; 625(1-3):63-72. PubMed ID: 19836385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
    Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
    Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revisiting the role of TRAIL/TRAIL-R in cancer biology and therapy.
    Singh D; Tewari M; Singh S; Narayan G
    Future Oncol; 2021 Feb; 17(5):581-596. PubMed ID: 33401962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRAIL receptor signaling and therapeutics.
    Abdulghani J; El-Deiry WS
    Expert Opin Ther Targets; 2010 Oct; 14(10):1091-108. PubMed ID: 20819019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined modality therapy with TRAIL or agonistic death receptor antibodies.
    Amm HM; Oliver PG; Lee CH; Li Y; Buchsbaum DJ
    Cancer Biol Ther; 2011 Mar; 11(5):431-49. PubMed ID: 21263219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TRAIL-based therapeutic approaches for the treatment of pediatric malignancies.
    Gasparini C; Vecchi Brumatti L; Monasta L; Zauli G
    Curr Med Chem; 2013; 20(17):2254-71. PubMed ID: 23458616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRAIL: a sword for killing tumors.
    Wang S
    Curr Med Chem; 2010; 17(29):3309-17. PubMed ID: 20712573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRAIL as a target in anti-cancer therapy.
    Wu GS
    Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents.
    Rowinsky EK
    J Clin Oncol; 2005 Dec; 23(36):9394-407. PubMed ID: 16361639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of death receptor pathways in oncology.
    de Vries EG; Timmer T; Mulder NH; van Geelen CM; van der Graaf WT; Spierings DC; de Hooge MN; Gietema JA; de Jong S
    Drugs Today (Barc); 2003; 39 Suppl C():95-109. PubMed ID: 14988748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting TRAIL towards the clinic.
    Mahalingam D; Oldenhuis CN; Szegezdi E; Giles FJ; de Vries EG; de Jong S; Nawrocki ST
    Curr Drug Targets; 2011 Dec; 12(14):2079-90. PubMed ID: 21777191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The long and winding road to cancer treatment: the TRAIL system.
    Palacios C; Yerbes R; Sanchez-Perez T; Martin-Perez R; Cano-Gonzalez A; Lopez-Rivas A
    Curr Pharm Des; 2014; 20(17):2819-33. PubMed ID: 23944369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing TRAIL/TRAIL death receptor-based cancer therapies.
    Yuan X; Gajan A; Chu Q; Xiong H; Wu K; Wu GS
    Cancer Metastasis Rev; 2018 Dec; 37(4):733-748. PubMed ID: 29541897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the Apo2L/TRAIL system for the therapy of autoimmune diseases and cancer.
    Martinez-Lostao L; Marzo I; Anel A; Naval J
    Biochem Pharmacol; 2012 Jun; 83(11):1475-83. PubMed ID: 22230480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway.
    Cretney E; Takeda K; Smyth MJ
    Int J Biochem Cell Biol; 2007; 39(2):280-6. PubMed ID: 17097329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNF-related apoptosis-inducing ligand: signalling of a 'smart' molecule.
    Manzo F; Nebbioso A; Miceli M; Conte M; De Bellis F; Carafa V; Franci G; Tambaro FP; Altucci L
    Int J Biochem Cell Biol; 2009 Mar; 41(3):460-6. PubMed ID: 18243765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL.
    Hassanzadeh A; Farshdousti Hagh M; Alivand MR; Akbari AAM; Shams Asenjan K; Saraei R; Solali S
    J Cell Physiol; 2018 Oct; 233(10):6470-6485. PubMed ID: 29741767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy.
    Dai X; Zhang J; Arfuso F; Chinnathambi A; Zayed ME; Alharbi SA; Kumar AP; Ahn KS; Sethi G
    Exp Biol Med (Maywood); 2015 Jun; 240(6):760-73. PubMed ID: 25854879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is TRAIL the holy grail of cancer therapy?
    Newsom-Davis T; Prieske S; Walczak H
    Apoptosis; 2009 Apr; 14(4):607-23. PubMed ID: 19194800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway.
    Wang S
    Oncogene; 2008 Oct; 27(48):6207-15. PubMed ID: 18931688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.